Reinforced tissue matrices represent a hybrid approach to hernia repair. They combine a biologic extracellular matrix scaffold, derived from animal tissue, with permanent synthetic reinforcement woven into the structure. The idea is elegant: the biologic component encourages tissue integration and may tolerate contamination better than pure synthetics, while the synthetic framework provides the mechanical durability that purely biologic meshes have repeatedly failed to deliver. One such device, OviTex, has attracted growing interest among surgeons facing reconstructive scenarios where conventional options fall short.

Yet the evidence base for these hybrid implants has remained thin, and clear indication criteria have been lacking. To address this gap, a team of German abdominal wall surgeons led by Sebastian Schaaf of the Bundeswehrzentralkrankenhaus Koblenz assembled a multicenter case series combined with a structured expert consensus analysis. Their goal was not to prove that RTM meshes outperform synthetic, biologic, or biosynthetic alternatives, but rather to map the clinical scenarios in which experienced surgeons consider the implant justifiable at all.

The study collected 74 patients across six German surgical centers who had undergone complex abdominal wall reconstruction with an RTM mesh. The cohort was typical of the hardest cases in hernia surgery: mean age 63.9 years, median body mass index 30.2 kilograms per square meter, and more than three-quarters of patients carrying at least one risk factor for surgical site occurrence or recurrence. Obesity, diabetes, nicotine abuse, and chronic obstructive pulmonary disease were all common. Most patients presented with incisional hernias, and the median defect area reached 129 square centimeters, with over half of classifiable defects falling into the W3 category—the widest and most challenging tier.

Contamination was a defining feature of the cohort. Half of the procedures were classified as clean wounds, but roughly one-third involved clean-contaminated, contaminated, or dirty fields under the Centers for Disease Control and Prevention classification. The documented reasons for choosing an RTM mesh reflected this reality: large fascial defects or tissue loss accounted for 40.5 percent of indications, contaminated or potentially contaminated operative fields for 31.1 percent, high-risk patient profiles for 16.2 percent, and previous mesh implantation or recurrence for 14.9 percent. Bridging situations, loss of domain, and open abdomen reconstruction rounded out the list.

Operative technique varied widely, mirroring real-world decision-making. Intraperitoneal onlay mesh repair was the most frequently performed approach at 46.6 percent of cases, followed by retromuscular reconstruction at 20.5 percent. Bridging repair—placing the mesh as a substitute for absent fascia rather than reinforcing a closed fascial layer—was required in 12.3 percent of patients. Advanced adjunctive strategies, including transversus abdominis release, component separation, fascial traction, botulinum toxin application, and staged reconstruction with negative pressure wound therapy, were deployed in 16.4 percent of cases. The authors emphasize that bridging was reserved as a salvage strategy when primary fascial closure could not be achieved despite these measures, not as a preferred primary approach.

The outcomes paint a sobering but informative picture. Surgical site infection occurred in 20.3 percent of patients with available follow-up, mesh infection in 7.8 percent, and hernia recurrence in 12.3 percent. In-hospital mortality was 4.1 percent, and major complications classified as Clavien–Dindo grade IIIb or higher affected 38.3 percent of patients with complication data. Notably, however, all five mesh infections were managed successfully with local wound care and, in one case, an eight-week course of fluconazole for confirmed Candida colonization—without a single mesh explantation. This mesh salvage potential, the authors suggest, may warrant further investigation as a clinically relevant outcome in its own right.

The heart of the study, however, lies in its consensus analysis. Seven experienced abdominal wall surgeons independently reviewed standardized case summaries for all 74 patients and rated whether RTM implantation was a reasonable reconstructive option in each scenario. Consensus was predefined as agreement among at least 70 percent of raters—five of seven. Across 511 valid ratings, 68.9 percent supported RTM use overall, but formal consensus supporting implantation was reached in only 50 percent of cases. Agreement clustered tightly in the scenarios the researchers had anticipated: cases combining contamination or infection with large fascial defects drew the strongest support, while augmentation or bridging without infection attracted substantially lower consensus. Overall interrater reliability was fair, with a Fleiss’ kappa of 0.34, reflecting indication-dependent judgment rather than a uniformly applied algorithm.

The authors are careful about what these findings do and do not mean. The study is retrospective, lacks a comparative control group, and cannot establish whether RTM performs better, similarly, or worse than permanent synthetic or biosynthetic meshes. Follow-up was variable and relatively short, with a median of 12 months, meaning late recurrences may not yet have surfaced. Moreover, all seven experts had contributed cases to the series and assessed cases from their own institutions, introducing a potential confirmation bias that the authors openly acknowledge. The consensus assessment, they stress, should be read as an exploratory snapshot of current expert perception rather than an objective validation of RTM indications.

What the study does establish is a preliminary, phenotype-oriented framework for future research. The message for surgeons is clear: reinforced tissue matrices are not a routine alternative to permanent synthetic meshes, which remain the standard for ventral and incisional hernia repair thanks to their superior durability and cost-effectiveness. Randomized trials, including the landmark Rosen study published in JAMA Surgery in 2022, have already shown that purely biologic meshes carry higher recurrence rates and substantially higher costs than synthetics even in contaminated fields. RTM meshes may occupy a narrower niche—those high-complexity scenarios where contamination, prior infection, and massive tissue loss converge and conventional synthetics feel like a gamble. The authors now propose that these findings serve as a foundation for an international Delphi consensus process to define evidence-informed indications, followed by controlled comparative trials against contemporary synthetic and long-term absorbable biosynthetic meshes. Until then, the hybrid implant remains exactly what its name implies: a selective tool for the most difficult reconstructions, not a new default.

Subject of Research: Expert consensus on selective use of reinforced tissue matrix meshes in complex abdominal wall reconstruction

Article Title: Selective use of reinforced tissue matrix in complex abdominal wall reconstruction: a multicenter consensus analysis

Article References: Schaaf, S., Mones, T., Mai, P., Hoedt, N.-T., Götz, M., Willms, A., & Woeste, G. (2026). Selective use of reinforced tissue matrix in complex abdominal wall reconstruction: a multicenter consensus analysis. Journal of Abdominal Wall Surgery, 5, Article 17323. https://doi.org/10.3389/jaws.2026.17323

Image Credits: AI Generated

DOI: 10.3389/jaws.2026.17323

Keywords: abdominal wall reconstruction, hernia repair, reinforced tissue matrix, mesh infection, contaminated surgical field, expert consensus, biologic mesh, synthetic mesh, bridging repair, incisional hernia, surgical site infection, Fleiss kappa